Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 9.27 · gapped below the open, then crossed back over prior close. High/low 9.35 at 2:45 pm ET, 9.11 at 9:30 am ET.
Puma Biotechnology, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under the Pfizer Agreement, Pfizer was obligated to transfer to us certain information, records, regulatory filings, materials and inventory controlled by Pfizer and relating to or useful for developing these compounds and to continue to conduct certain ongoing clinical studies until a certain time.”
FILING10-K0001437749-26-005891cik 0001401667
“In September 2022, we entered into an exclusive license agreement with Takeda to license the worldwide research and development and commercial rights to alisertib.”
FILING10-K0001437749-26-005891cik 0001401667
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.”
FILING10-K0001437749-26-005891cik 0001401667
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.”
FILING10-K0001437749-26-005891cik 0001401667
“During the second quarter of 2020, we entered into a sub-license agreement (the "Bixink Agreement") with Bixink Therapeutics Co., Ltd. ("Bixink").”
FILING10-K0001437749-26-005891cik 0001401667
“Under the terms of the Knight Agreement, we will be solely responsible for the manufacturing and supply of the licensed products to Knight, but under limited circumstances Knight may obtain the right to manufacture the licensed products under the supply agreement.”
FILING10-K0001437749-26-005891cik 0001401667
“During the first quarter of 2018, we entered into a sub-license agreement (the "Medison Agreement"), with Medison Pharma Ltd. ("Medison").”
FILING10-K0001437749-26-005891cik 0001401667
“Under the terms of the Pierre Fabre Agreement, as amended, we are obligated to supply Pierre Fabre with the licensed products in accordance with the related supply agreement.”
FILING10-K0001437749-26-005891cik 0001401667
“On March 30, 2018, we entered into a sub-license agreement (the "Pint Agreement"), with Pint Pharma International SA ("Pint").”
FILING10-K0001437749-26-005891cik 0001401667
“The specialty pharmacy network sells directly to patients and consists of Accredo, CVS, ONCO 360, Optum and Biologics.”
FILING10-K0001437749-26-005891cik 0001401667
“The specialty pharmacy network sells directly to patients and consists of Accredo, CVS, ONCO 360, Optum and Biologics.”
FILING10-K0001437749-26-005891cik 0001401667
“On February 24, 2021, we resolved a dispute with our former partner CANbridge Biomed Limited and terminated our sub-license agreement.”
FILING10-K0001437749-26-005891cik 0001401667
“Within the STA Territory, STA will be generally responsible for regulatory and commercialization activities, and we will be solely responsible for the manufacturing and supply of the licensed product under a supply agreement entered into between the parties.”
FILING10-K0001437749-26-005891cik 0001401667
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.”
FILING10-K0001437749-26-005891cik 0001401667
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.”
FILING10-K0001437749-26-005891cik 0001401667
“The specialty pharmacy network sells directly to patients and consists of Accredo, CVS, ONCO 360, Optum and Biologics.”
FILING10-K0001437749-26-005891cik 0001401667
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.”
FILING10-K0001437749-26-005891cik 0001401667
“The specialty pharmacy network sells directly to patients and consists of Accredo, CVS, ONCO 360, Optum and Biologics.”
FILING10-K0001437749-26-005891cik 0001401667
Watchlist prices, news filtered to it, and its next report on your desk.
Puma Biotechnology, Inc. has 2 disclosed suppliers and 16 disclosed customers. Each one is named in an SEC filing, either Puma Biotechnology, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
PBYI (Puma Biotechnology, Inc.) has 2 disclosed suppliers and 16 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: MCK −1.38%, in the health bundle.